Drug Trial Radar · NCT03241550
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Last checked: Nov 20, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Oct 2, 2017
Primary completion
Jul 5, 2019
Study completion Jul 5, 2019
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Basilea Pharmaceutica International Ltd
- First posted
- Aug 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the pharmacokinetics (PK), safety and tolerability of multiple doses of intravenous (IV) and oral isavuconazonium sulfate administered daily in pediatric patients. The PK data will be utilized to establish a pediatric population PK model of isavuconazole, the active moiety of isavuconazonium sulfate.
Conditions
- Hematological Malignancy
Interventions
isavuconazonium sulfate - intravenousDrug
IV infusion
isavuconazonium sulfate - oralDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) of isavuconazole in plasma: Cmax at steady stateTime frame: Up to 7 days
- PK of isavuconazole in plasma: AUCtauTime frame: Up to 7 days
- PK of isavuconazole in plasma: tmaxTime frame: Up to 7 days
- PK of isavuconazole in plasma: CtroughTime frame: Up to 28 days
- PK of isavuconazole in plasma: CLTime frame: Up to 28 days
- PK of isavuconazole in plasma: VssTime frame: Up to 28 days
- PK of isavuconazole in plasma: AUCssTime frame: Up to 28 days
- PK of isavuconazole in plasma: t 1/2Time frame: Up to 28 days
- Safety assessed by nature, frequency and severity of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 58 days
- Number of patients with vital sign abnormalities and/or adverse eventsTime frame: Up to 28 days
- Number of patients with laboratory value abnormalities and/or adverse eventsTime frame: Up to 28 days
- Safety assessed by routine 12- lead electrocardiogram (ECG)Time frame: Up to 28 days
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Miller Children's Hospital
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
CHOC Children's Hospital of Orange County
Orange, California
Nicklaus Children's Hospital
Miami, Florida
Emory University School of Medicine
Atlanta, Georgia
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Louisville
Louisville, Kentucky
Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota
Children's Mercy Kansas City
Kansas City, Missouri
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
University Hospital of Cleveland
Cleveland, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
The Children's Hospital at TriStar Centennial Medical Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Texas Children's Hospital
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.